ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals, Inc. announced on March 18, 2026 that it entered into the Tenth Amendment to its Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (rights agent).
• The Tenth Amendment changes only the Final Expiration Date for the rights issued under the Rights Agreement, moving the expiration from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026. The Rights Agreement otherwise remains unchanged.

Key Details

• Rights Agreement originally dated August 14, 2020 (filed with the SEC as Exhibit 4.1 to the Form 8‑A).
• The Company has previously amended the Final Expiration Date multiple times (notable prior changes: extended to June 2, 2024 by First Amendment; to March 31, 2025 by Second Amendment; and several short-term extensions in 2025–2026).
• Tenth Amendment executed March 18, 2026; new Final Expiration Date is noon (NYC) on March 24, 2026.
• The Tenth Amendment is attached as Exhibit 4.1 to the current 8-K filing.

Why It Matters

• For investors, this filing means the Section 382 rights remain in effect for an additional short period (through March 24, 2026); Enzon’s management states the extension is in the company’s and stockholders’ best interests.
• Because the amendment only extends the expiration date and does not change other terms, it preserves the current rights framework and any protections or limitations those rights create until the new expiration date.